Dr. Dan Rohrer, PhD

Chief Technology Officer at AbTherx

Speaker

Dan is the Chief Technology Officer of AbTherx. He has over 25 years of broad experience in therapeutic drug discovery. Over the last 20 years, Dan and his scientific teams have specialized in creating therapeutic antibody discovery platforms in transgenic mice, including managing and refining the HuMAb Mouse^® platform – the most successful platform based on the number of FDA approvals to date. Updating this technology to meet new antibody therapeutic modality needs has resulted in the creation of the novel and differentiated Atlas™ Mice antibody platform which is poised to address the evolving antibody therapeutics market. Dan has an established background and publication record in transgenic methodologies and G-protein coupled receptors, and he is recognized throughout the industry for his leadership of therapeutic discovery campaigns.